Marina Gelman

Director of Translational Science at Calithera Biosciences, Inc.

Marina Gelman

Marina Gelman

Director of Translational Science at Calithera Biosciences, Inc.

Overview
RelSci Relationships

314

Contact Data
Trying to get in touch with Marina Gelman? Subscribe today to access their professional contact information and receive a one time promotion of free Contact Data credits!
Relationships
RelSci Relationships are individuals Marina Gelman likely has professional access to. A relationship does not necessarily indicate a personal connection.

Founder, President & Chief Executive Officer at Calithera Biosciences, Inc.

Relationship likelihood: Strong

Senior Vice President of Research at Calithera Biosciences, Inc.

Relationship likelihood: Strong

Scientific Founder at Cleave Biosciences, Inc.

Relationship likelihood: Strong

Executive Vice Chair at San Francisco Conservatory of Music

Relationship likelihood: Strong

General Partner at Advanced Technology Ventures

Relationship likelihood: Strong

Co-Founder at Sunesis Pharmaceuticals, Inc.

Relationship likelihood: Strong

Vice President, Head-People & Culture at Calithera Biosciences, Inc.

Relationship likelihood: Strong

Chairman & Chief Executive Officer at Wellington Management Company LP

Relationship likelihood: Strong

Senior Vice President, General Counsel & Chief Compliance Officer at Calithera Biosciences, Inc.

Relationship likelihood: Strong

Senior Vice President of Development at Calithera Biosciences, Inc.

Relationship likelihood: Strong

Paths to Marina Gelman
Potential Connections via
Relationship Science
You
Marina Gelman
Director of Translational Science at Calithera Biosciences, Inc.
Career History
Director of Translational Science
Current

Calithera Biosciences, Inc. is a clinical-stage biopharmaceutical company, which engages in discovering and developing novel small molecule drugs directed against tumor metabolism and tumor immunology targets for the treatment of cancer. It offers programs such as Pipeline, Glutaminase Inhibitor, and Arginase Inhibitor. The company was founded by James A. Wells and Susan M. Molineaux on March 9, 2010 and is headquartered in South San Francisco, CA.

Senior Scientist
Tenure Unconfirmed

Rigel Pharmaceuticals, Inc. operates as a clinical stage biotechnology company. It discovers and develops novel, targeted drugs in the therapeutic areas of immunology, oncology and immune oncology. It focuses on intracellular signaling pathways and related targets that are critical to disease mechanisms. Its current product development programs include Fostamatinib Oral SYK Inhibitor and R348 Topical Ophthalmic JAK/SYK Inhibitor. The company was founded by Donald G. Payan, Garry P. Nolan and Ronald B. Garren on June 14, 1996 and is headquartered in South San Francisco, CA.

Other Affiliations

Marina Gelman is affiliated with Calithera Biosciences, Inc., Rigel Pharmaceuticals, Inc.

This web site is not endorsed by, directly affiliated with, maintained, authorized, or sponsored by Marina Gelman. The use of any trade name or trademark is for identification and reference purposes only and does not imply any association with the trademark holder. The Presence of Marina Gelman's profile does not indicate a business or promotional relationship of any kind between RelSci and Marina Gelman.